INDV vs. HCM, HIK, GNS, SPI, ONT, CRW, UPR, PRTC, AMS, and CTEC
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include HUTCHMED (HCM), Hikma Pharmaceuticals (HIK), Genus (GNS), Spire Healthcare Group (SPI), Oxford Nanopore Technologies (ONT), Craneware (CRW), Uniphar (UPR), PureTech Health (PRTC), Advanced Medical Solutions Group (AMS), and ConvaTec Group (CTEC). These companies are all part of the "medical" sector.
Indivior (LON:INDV) and HUTCHMED (LON:HCM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
85.6% of Indivior shares are held by institutional investors. Comparatively, 34.3% of HUTCHMED shares are held by institutional investors. 3.3% of Indivior shares are held by insiders. Comparatively, 42.9% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Indivior and Indivior both had 1 articles in the media. Indivior's average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.
Indivior has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
Indivior received 360 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 80.35% of users gave Indivior an outperform vote while only 78.40% of users gave HUTCHMED an outperform vote.
HUTCHMED has lower revenue, but higher earnings than Indivior. HUTCHMED is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior currently has a consensus price target of GBX 2,515, indicating a potential upside of 74.53%. Given Indivior's higher probable upside, equities analysts clearly believe Indivior is more favorable than HUTCHMED.
HUTCHMED has a net margin of 12.03% compared to Indivior's net margin of 0.44%. HUTCHMED's return on equity of 14.65% beat Indivior's return on equity.
Summary
Indivior beats HUTCHMED on 8 of the 15 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
